Talactoferrin: Phase III data

The double-blind, international Phase III FORTIS-M trial in 742 stage IIIb/IV NSCLC patients who have failed >=2 prior therapies showed that twice-daily 1.5 g oral talactoferrin plus best supportive care (BSC) missed